Drug Database
CA

caffeine citrate (Cafnea)

✓ Approved

Phebra · Small Molecule · Small Molecule

What is caffeine citrate?

caffeine citrate is a small molecule developed by Phebra. It is approved for therapeutic indications via injectable (others) or oral (po).

Drug Profile

Brand NamesCafnea
CompanyPhebra
Drug ClassSmall Molecule
RouteInjectable (Others), Oral (PO)
StatusApproved

Therapeutic Indications

caffeine citrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersApnoea✓ Approved

Related Research Articles

PubMedJournal of hazardous materials2026-07-17

Ecological risk assessment of caffeine in global aquatic ecosystems: From land to sea.

Fan Bo B, Guo Xiaolong X, Zhao Baoyi B, Zhang Xinyue X et al.

Caffeine, as a marker of human activity, has been widely detected in aquatic environments worldwide. This study analyzed caffeine concentrations in aquatic environments across 85 countries/regions to evaluate its ecological risks to freshwater and marine species. Based on species sensitivity distribution (SSD) curves, a chronic freshwater predicted no-effect concentration (PNEC) of 0.052 μg/L was derived, which may serve as a useful screening benchmark for global ecological risk assessment, pending further refinement with expanded chronic toxicity datasets. The derived chronic seawater PNEC (0.14 μg/L) in this study was only used as a preliminary screening threshold for caffeine risk. A multi-dimensional quantitative assessment of global ecological risks was performed via integrated application of risk quotient (RQ) based on PNEC, potentially affected fraction (PAF) and joint probability curve (JPC). Results showed 83.67% of global freshwater monitoring sites posed high risks (RQ > 1). PAF analysis indicated caffeine concentrations in 71.95% of freshwater monitoring sites might adversely affect over 5% of freshwater species, while JPC revealed a 13.29% risk probability to 5% of freshwater species. Based on Monte Carlo predictions, the median RQ for caffeine in pore water of freshwater sediment was 0.051, indicating the low risk (RQ < 0.1). In coastal monitoring sites, 50.52% of global coastal monitoring sites posed high risks. PAF analysis showed 32.99% of coastal monitoring sites threatened over 5% of marine species and JPC demonstrated a 34.16% risk probability to 5% of marine species. High-risk areas seem to be coupled with high coffee/tea consumption and limited wastewater treatment, implying that improving the treatment efficiency of WWTPs is crucial for lowering risks.

PubMedClinical orthopaedics and related research2026-07-17

CORR Insights®: Is a Resorbable Citrate-based Bioceramic Device Associated With Osseous Integration? An Early Retrospective MRI Analysis.

DeCoster Thomas A TA

PubMedPhysiological research2026-07-17

Eight Weeks of Sprint Interval Training With Adding Caffeine Ingestion Leads to Greater Improvements in Health-Related Physiological Parameters in Obese Male Adults.

Zhiang J J, Song Q Q

The aim of this research was to examine the effects of an 8-week sprint interval training (SIT) intervention alongside caffeine (CAF) supplementation on the physiological adaptations related to the health of obese men. Thirty obese men volunteered to take part in this research and were randomly assigned to three distinct groups: Caffeine plus SIT (CAF+SIT, 6 mg·kg-1 body mass, n=10), Placebo plus SIT (PL+SIT, 6 mg·kg-1 body mass in cellulose, n=10), and Control (CON, n=10). The participants in the caffeine and placebo groups ingested their supplements three times weekly, one hour prior to each SIT session over a period of eight weeks. Lower body strength, and cardiorespiratory fitness as well as body fat were assessed at baseline and following the intervention. Additionally, blood samples for evaluating fasting glucose and lipid profiles were collected 48 h before and after the SIT intervention. Both the CAF+SIT and PL+SIT groups demonstrated notable changes (p<0.05) in the assessed variables after the 8-week intervention period. Furthermore, the CAF+SIT group exhibited significantly greater adaptive responses (p<0.05) compared to the PL+SIT group in terms of fat mass reduction (Standardized mean difference [SMD]=-0.58), strength improvement (SMD=0.36), and cardiorespiratory fitness enhancement (SMD=0.41), as well as modifications in fasting glucose (SMD=-0.57), HDL (SMD=0.18), LDL (SMD=-0.80), cholesterol (SMD=-0.53), triglyceride (SMD=-0.48) and non-HDL (SMD=-1.14) following the intervention. The administration of CAF prior to SIT led to more significant decreases in fat mass and enhancements in strength and cardiorespiratory fitness. Additionally, it resulted in more notable alterations in fasting glucose and lipid profiles among obese men, thereby elucidating the beneficial effects of CAF when combined with SIT to enhance men's health. Key words Interval intervention " Supplementation " Obesity " Health.

PubMedbioRxiv : the preprint server for biology2026-07-17

Structures of the human sodium-citrate cotransporter NaCT with and without substrates.

Sauer David B DB, Song Jinmei J, Marden Jennifer J JJ, Wang Bing B et al.

The human sodium-citrate cotransporter NaCT imports various tri- and dicarboxylates into the cell as TCA cycle intermediates. This substrate uptake process is driven by an inward sodium gradient. The protein is a member of the Divalent Anion-Sodium Symporter (DASS) family. Whereas extensive biochemical and structural studies have been carried out for NaCT, how the substrate binding and translocation is coupled to the sodium gradient remains unclear. Here using single particle cryo-electron microscopy, we determined the structures of the human NaCT protein in three states: sodium-free, in the presence of sodium, and sodium- and substrate-bound. These structures suggest a simultaneous binding mechanism for sodium-substrate coupling, distinct from the sequential binding, conformational selection mechanism previously observed for the bacterial DASS protein VcINDY.

PubMedAnnales pharmaceutiques francaises2026-07-17

Design Space Exploration and Multi-Color Analytical Profiling of a BBD Assisted RP-HPLC Method for Simultaneous Estimation of Butamirate Citrate and Chlorpheniramine Maleate.

Bhaskar Siddhesh Sanjay SS, Zine Sandip Prabhakar SP, Bagul Vijay A VA, Tiwari Anand R AR et al.

Analytical Quality-by-Design principles were used to develop and validate a reverse-phase high-performance liquid chromatography method for the simultaneous quantification of butamirate citrate and chlorpheniramine maleate in pharmaceutical formulations. Box- Behnken Design systematically optimized three critical variables mobile phase pH, flow rate, and column temperature with response surface plots confirming robust chromatographic performance. Using an isocratic mobile phase of ethanol: water (40:60 v/v) containing 0.33% triethylamine and adjusted to pH 6.0 using 1% orthophosphoric acid, separation was accomplished on a Waters Spherisorb cyano column (250 mm × 4.6 mm, 5 μm) at 1.2 mL/min with photodiode array detection at 225 nm. Validation per ICH Q2(R2) demonstrated excellent linearity (r²=0.999) across 112-337 μg/mL and 10-30 μg/mL for both analytes, with percentage recoveries of 99% and 98%, respectively. Environmental sustainability was confirmed through Analytical Eco-scale (score: 80), Analytical Greenness metric (0.69), and Complex Modified Green Analytical Procedure Index (83). Analytical performance was evaluated using the Red Analytical Performance Index (70) and Multi-Color Assessment Tool (72.6%), collectively reflecting strong scope, sensitivity, accuracy, and precision. Reliable quantification of both compounds in pharmaceutical dosage forms is offered by a validated, environmentally friendly approach, supporting routine quality control and research applications.

PubMedMolecular biology reports2026-07-17

SLC25A1 drives lipid metabolic reprogramming promoting liver injury leading to hepatocellular carcinoma.

Shahid Mehak M, Ashfaq Isbah I, Haider Burhan B, Tayyeb Asima A

Cancer metabolism especially lipid metabolic reprogramming is considered one of the most important metabolic processes involved in hepatocellular carcinoma (HCC). Solute carrier family 25 member A1 (SLC25A1) is a citrate transporter present in mitochondrial membrane and emerged to play role in lipid metabolic reprogramming. This study aimed to elucidate the mechanistic role of SLC25A1 in lipid metabolic reprogramming and its therapeutic potential in HCC. In the current study, enhanced expression of SLC25A1 gene was observed in toxicant induced mouse model of HCC suggesting a correlation with initiation and development of HCC. However, the precise mechanistic involvement of SLC25A1 in HCC is unclear underscoring the need of an in depth study. Clinical relevance of SLC25A1 in HCC was primarily evaluated using The Cancer Genome Atlas database. The in silico results not only demonstrated a strong correlation between the expression of SLC25A1 and HCC but also associated it with poor survival. In depth gain of function analysis using mammalian expression vector, SLC25A1-PCMV3 in human cell lines exhibited enhanced cellular growth, invasion, and migration potentials of cells expressing SLC25A1. Notably, the overexpression of SLC25A1 was associated with increased de novo lipogenesis, consistent with metabolic reprogramming favoring cytosolic citrate utilizationas evident by upregulation of FASN, ACACA, ACLY, SCD1 and downregulation of IDH2 and OGDH. Virtual screening and molecular docking studies presented rutin, a natural flavonoid, as a potential inhibitor of SLC25A1. In vitro inhibition of SLC25A1 by treatment with rutin significantly suppressed SLC25A1 expression leading to reduced lipogenesis. Collectively, these findings propose SLC25A1 is associated with metabolic reprogramming in HCC and contribute to tumor progression.by promoting lipogenesis. Thus offering a promising therapeutic target for early intervention and treatment.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about caffeine citrate